Megace Es Generic Name & Formulations
Megestrol acetate 125mg/mL; oral susp; lemon-lime flavor.
Concentrated susp (125mg/mL)—5oz
Megace Es Indications
Anorexia, cachexia, or unexplained significant weight loss in patients diagnosed with AIDS.
Limitations of Use
Should only be instituted after treatable causes of weight loss are sought and addressed. Not for prophylactic use to avoid weight loss.
Megace Es Dosage and Administration
625mg/5mL per day.
Megace Es Contraindications
Megace Es Boxed Warnings
Megace Es Warnings/Precautions
Do not substitute with other megestrol suspensions (not interchangeable). History of thromboembolic disease. Monitor for signs/symptoms of adrenal insufficiency; consider empiric therapy if occurs. Diabetes. Renal impairment. Elderly. Fetal toxicity. Obtain (–) pregnancy test prior to initiation. Advise females of reproductive potential to use effective contraception during therapy. Nursing mothers: not recommended.
Megace Es Pharmacokinetics
Megace Es Interactions
May increase insulin requirements. Decreases indinavir levels.
Megace Es Adverse Reactions
Nausea, diarrhea, impotence, rash, flatulence, hypertension, asthenia; rare: adrenal insufficiency, breakthrough bleeding.
Megace Es Clinical Trials
Megace Es Note
Megace Es Patient Counseling